BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection

December 23, 2014 11:17 AM

16 0

BioCryst Pharmaceuticals, Inc. BCRX, -0.27% today announced results from a proof-of-concept study of its broad spectrum antiviral BCX4430 for the treatment of experimental Ebola virus infection in rhesus macaques, conducted at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

The primary goal of the study was to assess the effect of BCX4430 treatment on survival through Day 41 in animals infected with Ebola virus. Dosing of placebo or BCX4430 by intramuscular (i.m.) injection was initiated 30-120 minutes after virus challenge and continued twice a day (BID) for 14 days.

Read more

To category page